3-Fluoroamphetamine (3-FA) is a fluorinated analog of amphetamine in which a fluorine atom is placed at the 3-position (meta) of the phenyl ring. It belongs to the substituted amphetamine chemical class and is distinguished within the series by its position isomerism from 4-FA: while 4-fluoroamphetamine has significant entactogenic (MDMA-like) properties due to serotonin releasing activity, 3-FA is generally characterized as a more purely stimulant compound with primarily dopaminergic and noradrenergic activity.
Community reports describe 3-FA as producing focused stimulation, wakefulness, and mood elevation broadly comparable to amphetamine or 2-FMA, but with a somewhat shorter duration and slightly more pronounced euphoric quality than the ortho-substituted 2-FMA. It is considered to occupy a middle ground in the fluoroamphetamine series — less functionally "clean" than 2-FMA but less overtly entactogenic than 4-FA or 3-FMA. The onset is typically 30–60 minutes orally, with effects lasting 4–8 hours.
As with all research chemical stimulants, formal human pharmacological data for 3-FA are absent. The compound's effects are inferred from structural analogy, animal studies, and the substantial body of community self-reports accumulated in harm reduction forums. While the meta substitution is associated with less serotonergic releasing activity than the para position, the specific receptor binding profile of 3-FA has not been fully characterized.
Safety at a Glance
High Risk- Dose Reference Points
- Community-reported doses for 3-FA:
- Toxicity: Overview The toxicity profile of 3-FA has not been formally studied in humans. Based on its structural class and infe...
- Dangerous with: Atropa belladonna, Datura, Diphenhydramine, Harmala alkaloid, 25x-NBOMe, 2C-T-x, DOx (+2 more)
- Overdose risk: Stimulant overdose from 3-FA is a medical emergency primarily involving cardiovascular and neurol...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 4 hrs – 6 hrsHow It Feels
The onset of 3-FA announces itself more boldly than its positional isomers. Within twenty to forty minutes of oral ingestion, a rising wave of confident energy sweeps through the body. The chest warms, the pulse quickens, and a distinct euphoria begins to bloom, a bright, upward-pulling mood elevation that carries with it a desire to move, talk, and engage. This is not the quiet utility of the 2-fluorinated variants but something more recreational, more insistent in its pleasures.
As the experience climbs toward its peak over the next hour, the euphoria intensifies into something genuinely compelling. Conversations become animated and feel deeply satisfying. Social confidence surges, self-consciousness retreats, and there is a powerful sense that the world is fundamentally good and interesting. Music sounds outstanding, with enhanced rhythm perception and an almost physical pleasure in bass frequencies. The body is buzzing with clean, directed energy, warm and light, limbs eager for movement. The jaw clenches with noticeable force, the pupils widen, and the mouth dries, but these physical markers feel like background noise against the foreground of stimulated wellbeing.
At the peak, typically one to two hours in, 3-FA delivers a classic recreational stimulant profile. The euphoria is robust, the energy is abundant, and the sociability is nearly irresistible. There is a moderate empathogenic edge, a warmth toward others that falls short of MDMA territory but clearly exceeds baseline. Physical restlessness is pronounced: sitting still feels unnatural, and the body craves dancing, walking, or animated gesturing. Heart rate and blood pressure are notably elevated, appetite is entirely absent, and body temperature runs warm.
The comedown begins around four to five hours in and arrives with more friction than the functional fluoroamphetamines. As the euphoria drains away, a restless dissatisfaction takes its place, a sense that the glow has been turned off too soon. Fatigue builds, the jaw finally unclenches, and a mild but definite irritability may color the remaining hours. Sleep is difficult for some time after the primary effects fade. The following day may carry a residual tiredness and slightly lowered mood, proportional to the degree of euphoria that was borrowed the night before.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(5)
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Insomnia— A persistent inability to fall asleep or maintain sleep despite physical tiredness, often characteri...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Cognitive & Perceptual Effects
Cognitive(7)
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Empathy enhancement— A state of intensified compassion and emotional openness in which one feels deeply connected to othe...
- Irritability— Irritability is a sustained state of emotional reactivity in which the threshold for annoyance, frus...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Pharmacology
Mechanism of Action
3-FA is understood to act primarily as a dopamine and norepinephrine releasing agent — consistent with the amphetamine-type structural template — with substantially less serotonin releasing activity than 4-FA. The meta fluorine atom modulates the electronic density of the ring and affects binding at monoamine transporters, but the fundamental catecholamine releasing mechanism is preserved.
Based on structure-activity relationships in the fluoroamphetamine series, the 3-position substitution appears to produce an intermediate serotonergic profile — more serotonergic than 2-FMA (ortho), less so than 4-FA (para). This places 3-FA on the spectrum between pure stimulant and mild entactogen, though the entactogenic component is substantially weaker than in 4-FA.
Receptor Profile
- DAT — Primary releasing agent activity; dopamine increases drive stimulation and euphoria
- NET — Norepinephrine release contributes to wakefulness, focus, appetite suppression
- SERT — Some evidence for moderate serotonergic activity; less than 4-FA, potentially more than 2-FMA
Pharmacokinetics
No formal human studies exist. Community experience suggests:
- Onset: 30–60 minutes oral
- Peak: 1–3 hours
- Duration: 4–8 hours
- Shorter overall duration than 2-FMA; similar to amphetamine
Fluorine substitution at the meta position is expected to confer some metabolic resistance compared to unsubstituted amphetamine, potentially contributing to a moderately extended duration.
Detection Methods
Standard Drug Panel Inclusion
3-FA (3-Fluoroamphetamine) is a fluorinated amphetamine analogue that is generally not detected on standard 5-panel, 10-panel, or 12-panel immunoassay drug screens. The fluorine substitution on the phenyl ring alters the molecular structure sufficiently that most amphetamine-targeted antibodies in commercial immunoassays fail to recognize it. However, cross-reactivity varies between manufacturers and assay generations, so a false positive on the amphetamine channel cannot be entirely ruled out.
Urine Detection
Due to the structural similarity to amphetamine, 3-FA (3-Fluoroamphetamine) and its metabolites may persist in urine for approximately 2 to 4 days after a single dose. Chronic or heavy use can extend this window. The primary metabolites include deaminated and hydroxylated derivatives, though comprehensive metabolic profiling of 3-FA (3-Fluoroamphetamine) in humans remains limited. Standard immunoassay urine cups will typically return a negative result for 3-FA (3-Fluoroamphetamine) unless the specific assay has unusually broad cross-reactivity.
Blood and Saliva Detection
3-FA (3-Fluoroamphetamine) can be detected in blood and oral fluid for approximately 12 to 48 hours after ingestion. Blood testing is uncommon outside of clinical or forensic contexts. Oral fluid testing follows a similar window but is used primarily in roadside or workplace settings where immediate-use detection is the goal.
Hair Follicle Detection
Hair follicle analysis can theoretically detect 3-FA (3-Fluoroamphetamine) for up to 90 days. However, most commercial hair testing laboratories do not include fluorinated amphetamines in their standard panels. Detection requires specific method development using LC-MS/MS with reference standards for 3-FA (3-Fluoroamphetamine).
Confirmatory Testing
Gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) are the definitive methods for confirming the presence of 3-FA (3-Fluoroamphetamine). These techniques can distinguish 3-FA (3-Fluoroamphetamine) from amphetamine, methamphetamine, and other substituted amphetamines with high specificity. Reference standards for 3-FA (3-Fluoroamphetamine) must be available to the testing laboratory for positive identification.
Reagent Testing
Marquis reagent produces no reaction or a faint orange-brown color with 3-FA (3-Fluoroamphetamine), which differs from the orange-to-brown response seen with standard amphetamine. Mecke reagent typically shows no reaction. Simon's reagent can help differentiate primary amines from secondary amines in the amphetamine class. Mandelin reagent may produce a faint green-brown color. These reagent responses help distinguish 3-FA (3-Fluoroamphetamine) from MDMA, methamphetamine, and cathinones but cannot confirm identity on their own.
Interactions
| Substance | Status | Note |
|---|---|---|
| Atropa belladonna | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Datura | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Diphenhydramine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Harmala alkaloid | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Peganum harmala | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 25x-NBOMe | Unsafe | — |
| 2C-T-x | Unsafe | — |
| DOx | Unsafe | — |
| PCP | Unsafe | — |
| 1,3-Butanediol | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 25E-NBOH | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-2 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-21 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Alcohol | Uncertain | — |
| Caffeine | Uncertain | — |
| Cannabis | Uncertain | — |
| Cocaine | Uncertain | — |
| GBL | Uncertain | — |
History
Development and Emergence
3-Fluoroamphetamine entered the research chemical market as part of the broader fluoroamphetamine series that emerged in the early 2010s. Like its isomers 2-FA and 4-FA, it was synthesized as a structural analog of amphetamine and methamphetamine with fluorine substitutions at various ring positions to explore structure-activity relationships and as legal alternatives to controlled stimulants.
Position in the Fluoroamphetamine Series
The three primary fluoroamphetamines — 2-FA (ortho), 3-FA (meta), and 4-FA (para) — have distinct effect profiles largely traceable to their substitution positions. 3-FA has occupied a less prominent position in the market than 2-FMA or 4-FA, partly due to its intermediate profile that lacks the distinctive entactogenic pull of 4-FA or the "clean focus" reputation of 2-FMA. It nonetheless has a documented presence in European and North American research chemical markets.
Regulatory Landscape
3-FA remains unscheduled in many jurisdictions. However, as a close structural analog of amphetamine, it falls within analog act provisions in some countries, and regulatory attention to the fluoroamphetamine series has increased following incidents involving 4-FA.
Harm Reduction
Dose Reference Points
Community-reported doses for 3-FA:
- Threshold: ~10 mg oral
- Common: 20–40 mg oral
- Strong: 40–60 mg oral
Start at the low end to assess individual sensitivity.
Timing
While shorter than 2-FMA, 3-FA still has a multi-hour duration. Avoid late-day dosing to protect sleep. Evening use frequently results in insomnia.
Avoid Frequent Use
Tolerance develops rapidly. Limit to occasional use with multi-day breaks between sessions to preserve effectiveness and minimize dependence risk.
Dangerous Combinations
- MAOIs — Risk of hypertensive crisis, serotonin syndrome; absolute contraindication
- Lithium — Avoid; risk of cardiac arrhythmia
- Other stimulants — Additive cardiovascular stress
- Alcohol — Masks intoxication, increases cardiovascular strain
Test Your Substance
Fluoroamphetamine powders are visually indistinguishable. Reagent testing or analytical verification is recommended to confirm identity and purity.
Toxicity & Safety
Overview
The toxicity profile of 3-FA has not been formally studied in humans. Based on its structural class and inferred pharmacology (primarily dopaminergic/noradrenergic releasing agent with some serotonergic activity), it is expected to carry risks broadly similar to amphetamine, with the caveat that the serotonergic component introduces additional considerations.
Cardiovascular Risk
Sympathomimetic effects — elevated heart rate, blood pressure, vasoconstriction — are the primary acute physiological risk. These are comparable to or slightly greater than amphetamine at equivalent doses. Stimulant-naive individuals and those with cardiovascular conditions are at elevated risk.
Neurotoxicity
If 3-FA possesses meaningful serotonin releasing activity, repeated high-dose use may carry some serotonergic neurotoxicity risk, as has been documented for 4-FA and related compounds. The degree of this risk is unknown and highly dependent on dose, frequency, and individual susceptibility.
Psychological Risks
Standard stimulant class psychological risks apply: anxiety, agitation, paranoia at high doses, potential for stimulant psychosis with chronic heavy use, and depressive rebound during the comedown period.
Dependence
Dopaminergic releasing agents carry meaningful physical and psychological dependence potential. While 3-FA lacks the recreational profile of 4-FA, compulsive use patterns can develop, particularly in individuals with histories of stimulant use disorders.
Addiction Potential
moderately addictive with a high potential for abuse
Overdose Information
Stimulant overdose from 3-FA is a medical emergency primarily involving cardiovascular and neurological toxicity.
Signs of overdose: Extremely rapid or irregular heartbeat, chest pain, severe headache, dangerously elevated body temperature, seizures, agitation progressing to psychosis, confusion, and loss of consciousness.
Emergency response:
- Call emergency services immediately
- Keep the person cool (remove excess clothing, apply cool water)
- If seizures occur, protect the head and clear the area of hard objects
- If the person loses consciousness, place in recovery position
- Do not give the person more stimulants, caffeine, or depressants unless directed by medical professionals
Prevention: Pre-measure doses. Avoid redosing. Stay hydrated (but don't overhydrate). Take breaks from physical activity. Monitor heart rate if possible. Have someone present who can recognize warning signs.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Tolerance
| Full | develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 10 days |
Cross-tolerances
Legal Status
3-FA is currently a grey area compound within all parts of the world, meaning its regulation lies in a legal grey area and that it is not known to be specifically illegal ("scheduled") within any country. However, people may still be charged for its possession under certain circumstances such as under analogue laws and with intent to sell or consume.
China: As of October 2015 3-FA is a controlled substance in China.
France: As of december 2024, 3-FA is not explicitly scheduled. It is thus legal to possess, although in a grey area.
Germany: 3-FA is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
New Zealand: 3-FA is an amphetamine analogue, so is a Schedule 3 controlled substance in New Zealand.
Switzerland: 3-FA is a controlled substance specifically named under Verzeichnis E.
The Netherlands:** 3-FA is a controlled substance as of July 1, 2025.
Turkey:** 3-FA is classed as a drug and is illegal to possess, produce, supply, or import.
United Kingdom: 3-FA is considered a Class A drug as a result of the amphetamine analogue clause of the Misuse of Drugs Act 1971.
United States: 3-FA may be considered to be an analog of amphetamine, thus falling under the Federal Analogue Act. The Federal Analogue Act, 21 U.S.C. § 813, is a section of the United States Controlled Substances Act, allowing any chemical "substantially similar" to an illegal drug (in Schedule I or II) to be treated as if it were also in Schedule I or II, but only if it is intended for human consumption.
Responsible use
Designer drug
Stimulants
Amphetamine
Substituted amphetamines
3-FA (Wikipedia)
3-FA (Isomer Design)
Experience Reports (2)
Tips (9)
Do not combine different fluoroamphetamines (like 3-FA and 4-FA) together. The combined serotonergic and dopaminergic activity may be unpredictable and there is very little safety data on these combinations.
Stay hydrated while using 3-FA. Stimulants increase heart rate and body temperature while suppressing thirst signals. Sip water regularly, roughly 250-500ml per hour, more if dancing or in hot environments.
3-FA is often described as 'diet meth' — clear-headed, calmly stimulating, and nicely euphoric without the harsh comedown of stronger stimulants. Great for functional use.
Supplement magnesium glycinate when using 3-FA to reduce jaw clenching, muscle tension, and bruxism. Also maintain electrolytes, B vitamins, and vitamin C which are depleted faster under stimulant use.
Avoid binge patterns with 3-FA. Sleep deprivation combined with stimulant use dramatically increases psychosis risk after 48+ hours awake. If you find yourself redosing to avoid the comedown, that is a major warning sign.
40mg oral is a solid starting dose. Duration of main effects is about 5-6 hours. The comedown is mild compared to methamphetamine, though you may have difficulty sleeping for a few hours after effects wear off.
Community Discussions (2)
See Also
References (3)
- Amphetamine: new content for an old topic — Heal et al. Neuropsychopharmacology Reviews (2013)paper
- 3-FA - TripSit Factsheet
TripSit factsheet for 3-FA
tripsit - 3-FA - Wikipedia
Wikipedia article on 3-FA
wikipedia